Literature DB >> 17175182

Proliferation of activated CD1d-restricted NKT cells is down-modulated by lymphocyte activation gene-3 signaling via cell cycle arrest in S phase.

Hyun-Jung Byun1, Woon-Won Jung, Dong-Sup Lee, Sanghee Kim, Sang Joon Kim, Chung-Gyu Park, Hee Yong Chung, Taehoon Chun.   

Abstract

Upon antigenic stimulation, CD1d-restricted NKT cells quickly secrete large amounts of cytokines. This prompt response demonstrates that CD1d-restricted NKT cells may potentially prove to be useful therapeutic agents for the treatment of many diseases. Despite the clinical importance of CD1d-restricted NKT cells, the regulating mechanisms of this unique T cell population remain to be defined. We found murine LAG-3 is inducible on CD1d-restricted NKT cells as the result of a variety of stimulants such as concanavalin A (con A) and anti-CD3. Also, antigen-specific CD1d stimulation can elicit LAG-3 in CD1d-restricted NKT cells. Moreover, ectopic LAG-3 expression on CD1d-restricted NKT cells results in cell cycle arrest in the S phase. These results show that LAG-3 signaling on activated CD1d-restricted NKT cells may down-modulate NKT cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17175182     DOI: 10.1016/j.cellbi.2006.11.002

Source DB:  PubMed          Journal:  Cell Biol Int        ISSN: 1065-6995            Impact factor:   3.612


  12 in total

1.  Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model.

Authors:  Katherine A Waugh; Sonia M Leach; Brandon L Moore; Tullia C Bruno; Jonathan D Buhrman; Jill E Slansky
Journal:  J Immunol       Date:  2016-07-01       Impact factor: 5.422

2.  TCR-dependent and -independent activation underlie liver-specific regulation of NKT cells.

Authors:  Jeff J Subleski; Veronica L Hall; Thomas B Wolfe; Anthony J Scarzello; Jonathan M Weiss; Tim Chan; Deborah L Hodge; Timothy C Back; John R Ortaldo; Robert H Wiltrout
Journal:  J Immunol       Date:  2010-12-10       Impact factor: 5.422

Review 3.  LAG3 (CD223) as a cancer immunotherapy target.

Authors:  Lawrence P Andrews; Ariel E Marciscano; Charles G Drake; Dario A A Vignali
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

Review 4.  The Potential Role of Inhibitory Receptors in the Treatment of Psoriasis.

Authors:  Neha Shah; Sabina Sandigursky; Adam Mor
Journal:  Bull Hosp Jt Dis (2013)       Date:  2017-05

Review 5.  Roles, function and relevance of LAG3 in HIV infection.

Authors:  Colin G Graydon; Allison L Balasko; Keith R Fowke
Journal:  PLoS Pathog       Date:  2019-01-17       Impact factor: 6.823

Review 6.  LAG3's Enigmatic Mechanism of Action.

Authors:  Colin G Graydon; Shifa Mohideen; Keith R Fowke
Journal:  Front Immunol       Date:  2021-01-08       Impact factor: 7.561

7.  Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection.

Authors:  Shawn D Blackburn; Haina Shin; W Nicholas Haining; Tao Zou; Creg J Workman; Antonio Polley; Michael R Betts; Gordon J Freeman; Dario A A Vignali; E John Wherry
Journal:  Nat Immunol       Date:  2008-11-30       Impact factor: 25.606

Review 8.  Mixed Signals: Co-Stimulation in Invariant Natural Killer T Cell-Mediated Cancer Immunotherapy.

Authors:  Susannah C Shissler; Michael S Lee; Tonya J Webb
Journal:  Front Immunol       Date:  2017-11-01       Impact factor: 7.561

Review 9.  LAG-3: from molecular functions to clinical applications.

Authors:  Takumi Maruhashi; Daisuke Sugiura; Il-Mi Okazaki; Taku Okazaki
Journal:  J Immunother Cancer       Date:  2020-09       Impact factor: 13.751

Review 10.  NK Cell-Based Immune Checkpoint Inhibition.

Authors:  Muhammad Khan; Sumbal Arooj; Hua Wang
Journal:  Front Immunol       Date:  2020-02-13       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.